New Cell-Free System Efficiently Produces Functional Bovine Interferon-Gamma
Background
Interferon-gamma (IFN-γ) is a vital cytokine (a protein that signals between cells to regulate immunity) playing a critical role in the immune system of bovine species, essential for fighting infections and regulating immune responses. Its availability is crucial for veterinary research, diagnostics, and potential therapeutic applications in cattle health. However, developing an efficient and scalable method to produce functional bovine interferon-gamma has remained a significant challenge.
Results
The optimized cell-free expression system demonstrated remarkable efficiency, achieving a protein yield of up to 1.5 mg/mL of bovine interferon-gamma within a reaction time of just 6 hours. This represents a 3-fold increase in yield compared to previous conventional bacterial expression systems, which typically yield 0.5 mg/mL over 12-18 hours. Functional assays confirmed that the cell-free expressed bovine interferon-gamma was highly active, inducing a 43% increase in the proliferation of specific immune cells compared to a non-functional control protein (p<0.001). Furthermore, the expressed bIFN-γ showed comparable specific activity to commercially available recombinant bIFN-γ, with a minimum effective concentration of 5 ng/mL required to elicit a 50% maximal response in cell-based assays. The system also produced a high percentage of soluble, correctly folded protein, estimated at over 85% of the total yield, significantly reducing the need for refolding steps.
Why It Matters
This study provides a robust and rapid platform for producing high-quality, functional bovine interferon-gamma, which is critical for advancing veterinary research and diagnostics. The ability to quickly generate large quantities of active bIFN-γ could significantly accelerate studies on bovine immune responses to various pathogens and vaccine development. This efficient cell-free system could pave the way for more accessible and cost-effective production of therapeutic proteins for animal health, potentially leading to new treatments for infectious diseases in cattle. Future work will focus on scaling up the system for industrial production and evaluating the in vivo efficacy of the cell-free expressed bIFN-γ in animal models.